Emerging pharmacological treatment options for MAFLD

Area of Science:

• Hepatology
• Metabolic Diseases
• Clinical Trials

Background:

• Metabolic dysfunction-associated fatty liver disease (MAFLD) prevalence and incidence are increasing worldwide.
• MAFLD is associated with metabolic comorbidities like obesity, type 2 diabetes, hypertension, and hyperlipidemia, elevating mortality risk.
• Fat accumulation in MAFLD leads to inflammation, fibrosis, cirrhosis, and hepatocellular carcinoma.

Purpose of the Study:

• To review recent therapeutic pathways and drug targets for MAFLD.
• To focus on treatments with evidence from phase II/III clinical trials.
• To address the limited approved pharmacotherapies for MAFLD progression.

Main Methods:

• Literature review of recent scientific publications.
• Analysis of clinical trial data for MAFLD treatments.
• Focus on pathways and targets progressing through phase II/III trials.

Main Results:

• Identification of several novel therapeutic targets and pathways.
• Evidence of potential efficacy for specific drug candidates in clinical trials.
• Highlighting the need for effective MAFLD interventions.

Conclusions:

• Emerging therapeutic strategies show promise in managing MAFLD.
• Further clinical development is crucial to address the unmet need for MAFLD treatments.
• Targeting specific pathways offers a potential avenue to prevent MAFLD progression and complications.